Evolus (EOLS) Cash from Financing Activities (2017 - 2026)
Evolus' (EOLS) quarterly Cash from Financing Activities came in at $7.6 million in Q1 2026, up 567.14% YoY from $1.1 million in Q1 2025, and up 9794.81% on a QoQ basis from $77000.0 in Q4 2025.
Evolus (EOLS) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Cash from Financing Activities data on file, last reported at $7.6 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 567.14% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (up 21872.73% YoY) and the FY2025 annual result came in at $17.3 million, down 63.43% from the prior year.
- Cash from Financing Activities rose to $7.6 million in Q1 2026, from $77000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $45.7 million in Q1 2024 to a low of -$1.8 million in Q3 2025.
- A 5-year average of $6.6 million and a median of -$849000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 109.3% — and 2024, when it surged 3661.78%.
- Tracing EOLS's Cash from Financing Activities over 5 years: stood at -$1.5 million in 2022, then surged by 1651.58% to $23.5 million in 2023, then sank by 105.58% to -$1.3 million in 2024, then surged by 105.86% to $77000.0 in 2025, then soared by 9794.81% to $7.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $7.6 million (Q1 2026), $77000.0 (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | -365,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -365,000.00 |
| Jun 30, 2026 | -365,000.00 |
| Mar 31, 2026 | 7.62 Mn |
| Mar 31, 2026 | 7.62 Mn |
| Dec 31, 2025 | 77,000.00 |
| Dec 31, 2025 | 77,000.00 |
| Sep 30, 2025 | -1.77 Mn |
| Sep 30, 2025 | -1.77 Mn |
| Jun 30, 2025 | 20.66 Mn |
| Jun 30, 2025 | 20.66 Mn |
| Mar 31, 2025 | -1.63 Mn |
| Mar 31, 2025 | -1.63 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Mar 31, 2024 | 45.66 Mn |
| Mar 31, 2024 | 45.66 Mn |